NCT00041028View on ClinicalTrials.gov

EF5 in Assessing Tumor Response to Anticancer Therapy in Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

60

Participants

Timeline

Start Date

May 31, 2002

Primary Completion Date

September 30, 2007

Study Completion Date

April 30, 2014

Conditions

Lung Cancer

Interventions

DRUG

EF5

OTHER

flow cytometry

OTHER

immunohistochemistry staining method

Trial Locations (2)

27705

Duke Comprehensive Cancer Center, Durham

Veterans Affairs Medical Center - Durham, Durham

Sponsors

Lead Sponsor

Duke University

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Duke University

OTHER